Guido Cavaletti

List of Publications by Year
in descending order

376	17,646	13854	23514
papers	citations	67 h-index	111 g-index

405	405	405	14507
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2014, 32, 1941-1967.	0.8	976
2	Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. Journal of Clinical Oncology, 2020, 38, 3325-3348.	0.8	457
3	Chemotherapy-induced peripheral neurotoxicity (CIPN): An update. Critical Reviews in Oncology/Hematology, 2012, 82, 51-77.	2.0	441
4	Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro-Oncology, 2012, 14, iv45-iv54.	0.6	347
5	Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Annals of Neurology, 1994, 36, 416-424.	2.8	267
6	Chemotherapy-induced peripheral neurotoxicity. Nature Reviews Neurology, 2010, 6, 657-666.	4.9	267
7	Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. European Journal of Cancer, 2001, 37, 2457-2463.	1.3	241
8	Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 823-828.	3.3	238
9	The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Annals of Oncology, 2013, 24, 454-462.	0.6	232
10	Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat. Experimental Neurology, 2007, 204, 317-325.	2.0	228
11	Chemotherapy-Induced Peripheral Neurotoxicity assessment: A critical revision of the currently available tools. European Journal of Cancer, 2010, 46, 479-494.	1.3	222
12	The Total Neuropathy Score as an assessment tool for grading the course of chemotherapyâ€induced peripheral neurotoxicity: comparison with the National Cancer Instituteâ€Common Toxicity Scale. Journal of the Peripheral Nervous System, 2007, 12, 210-215.	1.4	204
13	Platinum-Induced Neurotoxicity and Preventive Strategies: Past, Present, and Future. Oncologist, 2015, 20, 411-432.	1.9	190
14	Regional variation of Guillain-BarrÃ© syndrome. Brain, 2018, 141, 2866-2877.	3.7	190
15	Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurology, The, 2012, 11, 493-502.	4.9	185
16	Clinical pattern and associations of oxaliplatin acute neurotoxicity. Cancer, 2013, 119, 438-444.	2.0	179
17	Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: A multimodal analysis. Neuroscience, 2007, 144, 1293-1304.	1.1	175
18	Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology, 2003, 61, 1297-1300.	1.5	157

#	Article	IF	Citations
19	Experimental Peripheral Neuropathy Induced in Adult Rats by Repeated Intraperitoneal Administration of Taxol. Experimental Neurology, 1995, 133, 64-72.	2.0	156
20	Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11199-11204.	3.3	149
21	Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMOâ€"EONSâ€"EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Annals of Oncology, 2020, 31, 1306-1319.	0.6	146
22	Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. Journal of the Peripheral Nervous System, 2006, 11, 135-141.	1.4	141
23	Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathologica, 1992, 84, 364-71.	3.9	138
24	Thalidomide sensory neurotoxicity. Neurology, 2004, 62, 2291-2293.	1.5	138
25	Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clinical Cancer Research, 2003, 9, 5756-67.	3.2	138
26	Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leukemia and Lymphoma, 2010, 51, 1178-1187.	0.6	136
27	Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Annals of Oncology, 2014, 25, 257-264.	0.6	136
28	Intraepidermal nerve fiber density in rat foot pad: neuropathologic-neurophysiologic correlation. Journal of the Peripheral Nervous System, 2005, 10, 202-208.	1.4	132
29	Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. NeuroToxicology, 2000, 21, 389-93.	1.4	131
30	Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer, 1995, 75, 1141-1150.	2.0	122
31	Interventions for preventing neuropathy caused by cisplatin and related compounds. The Cochrane Library, 2014, 2014, CD005228.	1.5	117
32	Cisplatin-Induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer, 1992, 69, 203-207.	2.0	116
33	Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. European Journal of Cancer, 2005, 41, 1460-1466.	1.3	116
34	Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 392-398.	0.9	116
35	Chemotherapy-induced peripheral neurotoxicity. Current Opinion in Neurology, 2015, 28, 500-507.	1.8	115
36	ApoE-modified solid lipid nanoparticles: A feasible strategy to cross the blood-brain barrier. Journal of Controlled Release, 2017, 249, 103-110.	4.8	110

#	Article	IF	Citations
37	Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 125-132.	0.9	108
38	Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncology, The, 2011, 12, 1151-1161.	5.1	107
39	Multimodal Assessment of Painful Peripheral Neuropathy Induced by Chronic Oxaliplatin-Based Chemotherapy in Mice. Molecular Pain, 2011, 7, 1744-8069-7-29.	1.0	105
40	Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Annals of Oncology, 2004, 15, 1439-1442.	0.6	100
41	A phosphotyrosine switch regulates organic cation transporters. Nature Communications, 2016, 7, 10880.	5.8	100
42	Mesenchymal Stem Cells Neuronal Differentiation Ability: A Real Perspective for Nervous System Repair?. Current Stem Cell Research and Therapy, 2011, 6, 82-92.	0.6	96
43	Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial. Neurotherapeutics, 2018, 15, 178-189.	2.1	92
44	Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. European Journal of Cancer, 2002, 38, 1832-1837.	1.3	90
45	Role of MAPKs in platinum-induced neuronal apoptosis. NeuroToxicology, 2009, 30, 312-319.	1.4	90
46	International Guillainâ€BarrÃ© Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillainâ€BarrÃ© syndrome. Journal of the Peripheral Nervous System, 2017, 22, 68-76.	1.4	89
47	Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. NeuroToxicology, 1997, 18, 137-45.	1.4	89
48	Bortezomibâ€induced painful neuropathy in rats: A behavioral, neurophysiological and pathological study in rats. European Journal of Pain, 2010, 14, 343-350.	1.4	88
49	Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies. Experimental Neurology, 2010, 226, 301-309.	2.0	88
50	Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: a long-term survey of ovarian cancer patients. Journal of Neurology, 1997, 244, 85-89.	1.8	87
51	Tubulin: A Target for Antineoplastic Drugs into the Cancer Cells but also in the Peripheral Nervous System. Current Medicinal Chemistry, 2009, 16, 1315-1324.	1.2	86
52	Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus. Hypertension, 2011, 58, 776-783.	1.3	86
53	Voltageâ€gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatinâ€induced peripheral neurotoxicity: Results from a prospective multicenter study. Cancer, 2013, 119, 3570-3577.	2.0	86
54	Protective Effect of Erythropoietin and Its Carbamylated Derivative in Experimental Cisplatin Peripheral Neurotoxicity. Clinical Cancer Research, 2006, 12, 2607-2612.	3.2	85

#	Article	IF	Citations
55	Chemotherapy-Induced Neuropathy. Current Treatment Options in Neurology, 2011, 13, 180-190.	0.7	85
56	Comparison of Neuropathy-Inducing Effects of Eribulin Mesylate, Paclitaxel, and Ixabepilone in Mice. Cancer Research, 2011, 71, 3952-3962.	0.4	85
57	Neuroactive Steroid Levels are Modified in Cerebrospinal Fluid and Plasma of Post-Finasteride Patients Showing Persistent Sexual Side Effects and Anxious/Depressive Symptomatology. Journal of Sexual Medicine, 2013, 10, 2598-2603.	0.3	84
58	Diabetes-induced myelin abnormalities are associated with an altered lipid pattern: protective effects of LXR activation. Journal of Lipid Research, 2012, 53, 300-310.	2.0	83
59	Neuroprotective effects of a ligand of translocator protein-18kDa (Ro5-4864) in experimental diabetic neuropathy. Neuroscience, 2009, 164, 520-529.	1.1	82
60	Glutamate transporters in platelets: EAAT1 decrease in aging and in Alzheimerâ€™s disease. Neurobiology of Aging, 2004, 25, 149-157.	1.5	79
61	Neuroactive steroids and peripheral neuropathy. Brain Research Reviews, 2008, 57, 460-469.	9.1	79
62	Neuroinflammatory Process Involved in Different Preclinical Models of Chemotherapy-Induced Peripheral Neuropathy. Frontiers in Immunology, 2020, 11, 626687.	2.2	76
63	Activation of the Liver X Receptor Increases Neuroactive Steroid Levels and Protects from Diabetes-Induced Peripheral Neuropathy. Journal of Neuroscience, 2010, 30, 11896-11901.	1.7	75
64	Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. NeuroToxicology, 1999, 20, 883-7.	1.4	75
65	Platinumâ€induced peripheral neurotoxicity: From pathogenesis to treatment. Journal of the Peripheral Nervous System, 2019, 24, S26-S39.	1.4	74
66	Neuropeptides and Morphological Changes in Cisplatin-Induced Dorsal Root Ganglion Neuronopathy. Experimental Neurology, 1996, 138, 93-104.	2.0	73
67	Bortezomib-induced peripheral neurotoxicity: an update. Archives of Toxicology, 2014, 88, 1669-1679.	1.9	73
68	Interventions for preventing neuropathy caused by cisplatin and related compounds. , 2011, , CD005228.		71
69	Carboplatin toxic effects on the peripheral nervous system of the rat. Annals of Oncology, 1998, 9, 443-447.	0.6	70
70	Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 729-734.	0.9	70
71	Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Annals of Oncology, 2012, 23, 3116-3122.	0.6	69
72	Bortezomib-Induced Painful Peripheral Neuropathy: An Electrophysiological, Behavioral, Morphological and Mechanistic Study in the Mouse. PLoS ONE, 2013, 8, e72995.	1.1	69

#	Article	IF	Citations
73	Lowering Plasma 1-Deoxysphingolipids Improves Neuropathy in Diabetic Rats. Diabetes, 2015, 64, 1035-1045.	0.3	69
74	Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma. Journal of Steroid Biochemistry and Molecular Biology, 2015, 146, 74-79.	1.2	69
75	Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology, 2011, 77, 1887-1895.	1.5	68
76	Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics. Nature Reviews Neurology, 2017, 13, 492-504.	4.9	68
77	Clinical presentation and outcome of Guillainâ€“BarrÃ© and related syndromes in relation to anti-ganglioside antibodies. Journal of the Neurological Sciences, 1999, 168, 78-84.	0.3	67
78	Longâ€term course of oxaliplatinâ€induced polyneuropathy: a prospective 2â€year followâ€up study. Journal of the Peripheral Nervous System, 2014, 19, 299-306.	1.4	67
79	Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Supportive Care in Cancer, 2016, 24, 5059-5068.	1.0	67
80	Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients. Journal of Steroid Biochemistry and Molecular Biology, 2017, 171, 229-235.	1.2	67
81	Neurotoxicity of Platinum Compounds: Comparison of the Effects of Cisplatin and Oxaliplatin on the Human Neuroblastoma Cell Line SH-SY5Y. Journal of Neuro-Oncology, 2004, 67, 65-73.	1.4	66
82	The Role of Oxidative Stress and Anti-Oxidant Treatment in Platinum-Induced Peripheral Neurotoxicity. Current Cancer Drug Targets, 2010, 10, 670-682.	0.8	65
83	Microbeam radiation therapy â€” grid therapy and beyond: a clinical perspective. British Journal of Radiology, 2017, 90, 20170073.	1.0	65
84	Chemotherapyâ€induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. Journal of the Peripheral Nervous System, 2011, 16, 228-236.	1.4	64
85	Trial designs for chemotherapy-induced peripheral neuropathy prevention. Neurology, 2018, 91, 403-413.	1.5	63
86	Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy. Cell Cycle, 2014, 13, 612-621.	1.3	62
87	The incidence and course of paraneoplastic neuropathy in women with epithelial ovarian cancer. Journal of Neurology, 1991, 238, 371-374.	1.8	60
88	Paclitaxel toxicity in post-mitotic dorsal root ganglion (DRG) cells. Anticancer Research, 2006, 26, 1065-70.	0.5	60
89	Glutamate Carboxypeptidase Inhibition Reduces the Severity of Chemotherapy-Induced Peripheral Neurotoxicity in Rat. Neurotoxicity Research, 2010, 17, 380-391.	1.3	59
90	The Italian multiple sclerosis register. Neurological Sciences, 2019, 40, 155-165.	0.9	59

#	Article	IF	Citations
91	Protective effects of glutathione on cisplatin neurotoxicity in rats. International Journal of Radiation Oncology Biology Physics, 1994, 29, 771-776.	0.4	58
92	Cisplatin-induced peripheral neuropathy: Neuroprotection by erythropoietin without affecting tumour growth. European Journal of Cancer, 2007, 43, 710-717.	1.3	58
93	Testosterone derivatives are neuroprotective agents in experimental diabetic neuropathy. Cellular and Molecular Life Sciences, 2007, 64, 1158-1168.	2.4	58
94	Docetaxelâ€induced peripheral neuropathy: protective effects of dihydroprogesterone and progesterone in an experimental model. Journal of the Peripheral Nervous System, 2009, 14, 36-44.	1.4	58
95	OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. Journal of Clinical Investigation, 2018, 128, 816-825.	3.9	57
96	Retinoic acid differentiated SH-SY5Y human neuroblastoma cells: an in vitro model to assess drug neurotoxicity. Anticancer Research, 1998, 18, 2477-81.	0.5	57
97	Effect on the peripheral nervous system of systemically administered dimethylsulfoxide in the rat: a neurophysiological and pathological study. Toxicology Letters, 2000, 118, 103-107.	0.4	55
98	Role of a preâ€existing neuropathy on the course of bortezomibâ€induced peripheral neurotoxicity. Journal of the Peripheral Nervous System, 2008, 13, 267-274.	1.4	55
99	Functional Magnetic Resonance Imaging of Rats with Experimental Autoimmune Encephalomyelitis Reveals Brain Cortex Remodeling. Journal of Neuroscience, 2015, 35, 10088-10100.	1.7	54
100	Peripheral Neuropathy Induced by Microtubule-Targeted Chemotherapies: Insights into Acute Injury and Long-term Recovery. Cancer Research, 2018, 78, 817-829.	0.4	54
101	Effect of trans-resveratrol on signal transduction pathways involved in paclitaxel-induced apoptosis in human neuroblastoma SH-SY5Y cells. Neurochemistry International, 2003, 42, 419-429.	1.9	53
102	Vitamin E intake and quality of life in amyotrophic lateral sclerosis patients: a follow-up case series study. Neurological Sciences, 2006, 27, 190-193.	0.9	52
103	NGF protects Dorsal Root Ganglion neurons from oxaliplatin by modulating JNK/Sapk and ERK1/2. Neuroscience Letters, 2010, 486, 141-145.	1.0	52
104	Neuroprotective Effects of Progesterone in Chronic Experimental Autoimmune Encephalomyelitis. Journal of Neuroendocrinology, 2012, 24, 851-861.	1.2	52
105	Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth. Neurobiology of Disease, 2018, 111, 59-69.	2.1	52
106	Susceptibility of different mouse strains to oxaliplatin peripheral neurotoxicity: Phenotypic and genotypic insights. PLoS ONE, 2017, 12, e0186250.	1.1	52
107	Effect of Recombinant Human Nerve Growth Factor on Cisplatin Neurotoxicity in Rats. Experimental Neurology, 1999, 159, 551-558.	2.0	51
108	Validation of the Italian version of the Neuropathic Pain Symptom Inventory in peripheral nervous system diseases. Neurological Sciences, 2009, 30, 99-106.	0.9	51

#	Article	IF	Citations
109	The Glutamatergic Neurotransmission in the Central Nervous System. Current Medicinal Chemistry, 2012, 19, 1269-1276.	1.2	51
110	Lack of Sterol Regulatory Element Binding Factor-1c Imposes Glial Fatty Acid Utilization Leading to Peripheral Neuropathy. Cell Metabolism, 2015, 21, 571-583.	7.2	51
111	Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20). Quality of Life Research, 2017, 26, 2999-3010.	1.5	51
112	Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy. Experimental Neurology, 2018, 307, 129-132.	2.0	51
113	Experimental cisplatin neuronopathy in rats and the effect of retinoic acid administration. Journal of Neuro-Oncology, 1998, 36, 31-40.	1.4	50
114	Expression and distribution of â€˜high affinityâ€™ glutamate transporters GLT1, GLAST, EAAC1 and of GCPII in the rat peripheral nervous system. Journal of Anatomy, 2008, 213, 539-546.	0.9	50
115	Recent Development, Applications, and Perspectives of Mesoporous Silica Particles in Medicine and Biotechnology. Current Medicinal Chemistry, 2009, 16, 3054-3063.	1.2	50
116	Creutzfeldtâ€“Jakob disease with a novel four extra-repeat insertional mutation in the PrP gene. Neurology, 2000, 55, 405-410.	1.5	49
117	Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor. Neuroscience Letters, 2002, 322, 103-106.	1.0	49
118	Weekly cisplatin +- glutathione in relapsed ovarian carcinoma. International Journal of Gynecological Cancer, 1995, 5, 81-86.	1.2	48
119	Neuroactive steroid levels in plasma and cerebrospinal fluid of male multiple sclerosis patients. Journal of Neurochemistry, 2014, 130, 591-597.	2.1	48
120	Chemotherapyâ€induced peripheral neurotoxicity (<scp>CIPN</scp>): what we need and what we know. Journal of the Peripheral Nervous System, 2014, 19, 66-76.	1.4	48
121	A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): The study protocol [EudraCT no.: 2006-000032-27]. Pharmacological Research, 2006, 54, 436-441.	3.1	47
122	Bortezomib Treatment Produces Nocifensive Behavior and Changes in the Expression of TRPV1, CGRP, and Substance P in the Rat DRG, Spinal Cord, and Sciatic Nerve. BioMed Research International, 2014, 2014, 1-19.	0.9	47
123	Bortezomibâ€•and thalidomideâ€induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. American Journal of Hematology, 2014, 89, 1085-1091.	2.0	45
124	Extracorporeal photochemotherapy: a safety and tolerability pilot study with preliminary efficacy results in refractory relapsing-remitting multiple sclerosis. Neurological Sciences, 2006, 27, 24-32.	0.9	44
125	Bortezomib-induced peripheral neurotoxicity: still far from a painless gain. Haematologica, 2007, 92, 1308-1310.	1.7	44
126	Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice. Journal of Clinical Investigation, 2020, 130, 4601-4606.	3.9	44

#	Article	IF	Citations
127	The Combined Therapeutical Effect of Metal-based Drugs and Radiation Therapy: The Present Status of Research. Current Medicinal Chemistry, 2014, 21, 2237-2265.	1.2	44
128	Chemotherapy-induced peripheral neurotoxicity. Expert Opinion on Drug Safety, 2004, 3, 535-546.	1.0	43
129	Ethoxyquin provides neuroprotection against cisplatin-induced neurotoxicity. Scientific Reports, 2016, 6, 28861.	1.6	43
130	Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, jnnp-2019-320969.	0.9	43
131	Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity. Archives of Toxicology, 2020, 94, 2517-2522.	1.9	43
132	Beneficial Effects of PKF275-055, a Novel, Selective, Orally Bioavailable, Long-Acting Dipeptidyl Peptidase IV Inhibitor in Streptozotocin-Induced Diabetic Peripheral Neuropathy. Journal of Pharmacology and Experimental Therapeutics, 2012, 340, 64-72.	1.3	41
133	Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer.. Journal of Clinical Oncology, 1997, 15, 199-206.	0.8	40
134	Interventions for preventing neuropathy caused by cisplatin and related compounds. , 2007, , CD005228.		40
135	Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations. Supportive Care in Cancer, 2014, 22, 1161-1169.	1.0	39
136	Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer. Journal of Pain and Symptom Management, 2017, 54, 701-706.e1.	0.6	39
137	High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats. Journal of Neuroinflammation, 2018, 15, 232.	3.1	39
138	Guillain-BarrÃ© syndrome after SARS-CoV-2 infection in an international prospective cohort study. Brain, 2021, 144, 3392-3404.	3.7	39
139	CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats. Journal of Pain Research, 2012, 5, 151.	0.8	38
140	Human platelets express the synaptic markers VGLUT1 and 2 and release glutamate following aggregation. Neuroscience Letters, 2006, 404, 262-265.	1.0	37
141	Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. Cancer Chemotherapy and Pharmacology, 2012, 70, 899-902.	1.1	37
142	Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: An Underdiagnosed Clinical Entity?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e553-e560.	1.8	37
143	Chemotherapy-induced peripheral neuropathy clinical trials. Neurology, 2017, 89, 859-869.	1.5	37
144	Chemotherapyâ€induced peripheral neurotoxicity: A multifaceted, still unsolved issue. Journal of the Peripheral Nervous System, 2019, 24, S6-S12.	1.4	37

#	Article	IF	Citations
145	Hemorrhagic infarction: risk factors, clinical and tomographic features, and outcome A case-control study. Acta Neurologica Scandinavica, 1989, 80, 226-231.	1.0	36
146	Consistence and discrepancy of neuropathic pain screening tools DN4 and ID-Pain. Neurological Sciences, 2013, 34, 373-377.	0.9	36
147	Correspondence between neurophysiological andÂclinical measurements of chemotherapyâ€induced peripheral neuropathy: secondary analysis of data fromÂthe <scp>Clâ€PeriNomS</scp> study. Journal of the Peripheral Nervous System, 2014, 19, 127-135.	1.4	36
148	Design and Synthesis of Chitosanâ€"Gelatin Hybrid Hydrogels for 3D Printable in vitro Models. Frontiers in Chemistry, 2020, 8, 524.	1.8	36
149	Polyneuropathy due to cobalamin deficiency in the rat. Journal of the Neurological Sciences, 1998, 156, 18-29.	0.3	35
150	Long-lasting neuropsychological changes after a single high altitude climb. Acta Neurologica Scandinavica, 1993, 87, 103-105.	1.0	35
151	Effect of the chronic combined administration of cisplatin and paclitaxel in a rat model of peripheral neurotoxicity. European Journal of Cancer, 2009, 45, 656-665.	1.3	35
152	Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS). European Journal of Cancer, 2013, 49, 2910-2918.	1.3	35
153	Dihydrotestosterone as a Protective Agent in Chronic Experimental Autoimmune Encephalomyelitis. Neuroendocrinology, 2015, 101, 296-308.	1.2	35
154	Persistent Memory Impairment After High Altitude Climbing. International Journal of Sports Medicine, 1990, 11, 176-178.	0.8	34
155	Tissue platinum concentrations and cisplatin schedules. Lancet, The, 1990, 336, 1003.	6.3	34
156	Regression of diabetic complications by islet transplantation in the rat. Diabetologia, 2009, 52, 2653-2661.	2.9	34
157	Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis. Journal of Neuroimmunology, 2010, 220, 104-107.	1.1	34
158	Genetic determinants of chronic oxaliplatinâ€induced peripheral neurotoxicity: a genomeâ€wide study replication and metaâ€analysis. Journal of the Peripheral Nervous System, 2015, 20, 15-23.	1.4	34
159	Experimental epothilone B neurotoxicity: Results of in vitro and in vivo studies. Neurobiology of Disease, 2009, 35, 270-277.	2.1	33
160	Epothilone-Induced Peripheral Neuropathy: A Review of Current Knowledge. Journal of Pain and Symptom Management, 2011, 42, 931-940.	0.6	33
161	A clinico-pathological and follow up study of 10 cases of essential type II cryoglobulinaemic neuropathy.. Journal of Neurology, Neurosurgery and Psychiatry, 1990, 53, 886-889.	0.9	32
162	Quantitative Detection of Epstein-Barr Virus DNA in Cerebrospinal Fluid and Blood Samples of Patients with Relapsing-Remitting Multiple Sclerosis. PLoS ONE, 2014, 9, e94497.	1.1	32

#	Article	IF	Citations
163	The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage. Orphanet Journal of Rare Diseases, 2018, 13, 176.	1.2	31
164	Management of Oxaliplatin-Induced Peripheral Sensory Neuropathy. Cancers, 2020, 12, 1370.	1.7	31
165	BRAIN DAMAGE AFTER HIGH-ALTITUDE CLIMBS WITHOUT OXYGEN. Lancet, The, 1987, 329, 101.	6.3	30
166	Advanced age and liability to oxaliplatinâ€induced peripheral neuropathy: <scp>post hoc</scp> analysis of a prospective study. European Journal of Neurology, 2013, 20, 788-794.	1.7	30
167	Age-related changes in the function and structure of the peripheral sensory pathway in mice. Neurobiology of Aging, 2016, 45, 136-148.	1.5	30
168	Toward the identification of neuroprotective agents: g-scale synthesis, pharmacokinetic evaluation and CNS distribution of (R)-RC-33, a promising Sigma1 receptor agonist. Future Medicinal Chemistry, 2016, 8, 287-295.	1.1	30
169	Cerebrospinal fluid analysis and the determination of oligoclonal bands. Neurological Sciences, 2017, 38, 217-224.	0.9	30
170	Pharmacotherapy options for managing chemotherapy-induced peripheral neurotoxicity. Expert Opinion on Pharmacotherapy, 2018, 19, 113-121.	0.9	30
171	Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity.. Neuropharmacology, 2020, 164, 107905.	2.0	30
172	Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis. Journal of Neuroimmunology, 2004, 151, 55-65.	1.1	29
173	Infantile Hereditary Neuropathy with Hypomyelination: Report of Two Siblings with Different Expressivity. Neuropediatrics, 1991, 22, 65-70.	0.3	28
174	Proteasome Inhibition: A Promising Strategy for Treating Cancer, but What About Neurotoxicity?. Current Medicinal Chemistry, 2008, 15, 3025-3035.	1.2	28
175	Neurotoxic effects of antineoplastic drugs: the lesson of pre-clinical studies. Frontiers in Bioscience - Landmark, 2008, Volume, 3506.	3.0	28
176	A Role for Hemopexin in Oligodendrocyte Differentiation and Myelin Formation. PLoS ONE, 2011, 6, e20173.	1.1	28
177	An ultrastructural study of neuronal changes in dorsal root ganglia (DRG) of rats after chronic cisplatin administrations. Histology and Histopathology, 1995, 10, 837-45.	0.5	28
178	Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat. Anticancer Research, 2002, 22, 4199-204.	0.5	28
179	Emerging role of mitogenâ€activated protein kinases in peripheral neuropathies. Journal of the Peripheral Nervous System, 2007, 12, 175-194.	1.4	27
180	Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP Database. European Journal of Neurology, 2020, 27, 136-143.	1.7	27

#	Article	IF	Citations
181	Neuro- and ototoxicity of high-dose carboplatin treatment in poor prognosis ovarian cancer patients. Anticancer Research, 1998, 18, 3797-802.	0.5	27
182	Cationic Liposomes Target Sites of Acute Neuroinflammation in Experimental Autoimmune Encephalomyelitis. Molecular Pharmaceutics, 2009, 6, 1363-1370.	2.3	26
183	Ultrasound assessment of oxaliplatinâ€induced neuropathy and correlations with neurophysiologic findings. European Journal of Neurology, 2013, 20, 188-192.	1.7	26
184	Pain in chemotherapyâ€induced peripheral neurotoxicity. Journal of the Peripheral Nervous System, 2017, 22, 156-161.	1.4	26
185	Oxaliplatin-induced neuropathy occurs through impairment of haemoglobin proton buffering and is reversed by carbonic anhydrase inhibitors. Pain, 2020, 161, 405-415.	2.0	26
186	Neurotoxicity of cisplatin +/- reduced glutathione in the first-line treatment of advanced ovarian cancer. International Journal of Gynecological Cancer, 1996, 6, 415-419.	1.2	25
187	Peripheral neurotoxicity of platinum-based chemotherapy. Nature Reviews Cancer, 2008, 8, 72-72.	12.8	25
188	Myelin structure is unaltered in chemotherapy-induced peripheral neuropathy. NeuroToxicology, 2012, 33, 1-7.	1.4	25
189	Low-dose glutathione administration in the prevention of cisplatin-induced peripheral neuropathy in rats. NeuroToxicology, 1994, 15, 701-4.	1.4	25
190	Exercise and Neuropathy: Systematic Review with Meta-Analysis. Sports Medicine, 2022, 52, 1043-1065.	3.1	25
191	Raschâ€Transformed Total Neuropathy Score clinical version (RTâ€TNSc^{Â©}) in patients with chemotherapyâ€induced peripheral neuropathy. Journal of the Peripheral Nervous System, 2015, 20, 328-332.	1.4	24
192	Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy. Muscle and Nerve, 2017, 55, 366-372.	1.0	24
193	Pathogenic role of delta 2 tubulin in bortezomib-induced peripheral neuropathy. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	24
194	Long-term peripheral neurotoxicity of cisplatin in patients with successfully treated epithelial ovarian cancer. Anticancer Research, 1994, 14, 1287-92.	0.5	24
195	Thalidomide Chemotherapy-Induced Peripheral Neuropathy: Actual Status and New Perspectives with Thalidomide Analogues Derivatives. Mini-Reviews in Medicinal Chemistry, 2009, 9, 760-768.	1.1	23
196	Sex differences in the manifestation of peripheral diabetic neuropathy in gonadectomized rats: A correlation with the levels of neuroactive steroids in the sciatic nerve. Experimental Neurology, 2011, 228, 215-221.	2.0	23
197	In vivo comparative study of the cytotoxicity of a liposomal formulation of cisplatin (lipoplatinâ„¢). Cancer Chemotherapy and Pharmacology, 2011, 68, 1001-1008.	1.1	23
198	Chemotherapy-induced peripheral neurotoxicity in immune-deficient mice: New useful ready-to-use animal models. Experimental Neurology, 2015, 264, 92-102.	2.0	23

#	Article	IF	Citations
199	Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve. Supportive Care in Cancer, 2018, 26, 3143-3151.	1.0	23
200	Focus on the Role of Glutamate in the Pathology of the Peripheral Nervous System. CNS and Neurological Disorders - Drug Targets, 2008, 7, 348-360.	0.8	23
201	Rapidly progressive multifocal motor neuropathy with phrenic nerve paralysis: effect of nocturnal assisted ventilation. Journal of Neurology, 1998, 245, 613-616.	1.8	22
202	The Neuroprotective Effect of Erythropoietin in Docetaxel-Induced Peripheral Neuropathy Causes No Reduction of Antitumor Activity in 13762 Adenocarcinoma-Bearing Rats. Neurotoxicity Research, 2010, 18, 151-160.	1.3	22
203	Diagnostic Validity of Optic Disc and Retinal Nerve Fiber Layer Evaluations in Detecting Structural Changes after Optic Neuritis. Ophthalmology, 2010, 117, 1256-1264.e1.	2.5	22
204	Anti-Multiple Myeloma Potential of Secondary Metabolites from Hibiscus sabdariffa. Molecules, 2019, 24, 2500.	1.7	22
205	ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine. Nature Communications, 2020, 11, 5938.	5.8	22
206	Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1092-1099.	0.9	22
207	Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neuropathy. Methods in Molecular Biology, 2014, 1175, 301-322.	0.4	22
208	The fundamental role of morphology in experimental neurotoxicology: the example of chemotherapy-induced peripheral neurotoxicity. Italian Journal of Anatomy and Embryology, 2012, 117, 75-97.	0.1	22
209	Neuronal drug transporters in platinum drugs-induced peripheral neurotoxicity. Anticancer Research, 2014, 34, 483-6.	0.5	22
210	Predicting Outcome in Guillain-BarrÃ© Syndrome. Neurology, 2022, 98, .	1.5	22
211	Women with pregnancy-related polymyositis and high serum CK levels in the newborn. Neurology, 2002, 58, 482-484.	1.5	21
212	Sex-dimorphic effects of dehydroepiandrosterone in diabetic neuropathy. Neuroscience, 2011, 199, 401-409.	1.1	21
213	Therapeutic potential of Mesenchymal Stem Cells for the treatment of diabetic peripheral neuropathy. Experimental Neurology, 2017, 288, 75-84.	2.0	21
214	High-Spatial-Resolution Three-dimensional Imaging of Human Spinal Cord and Column Anatomy with Postmortem X-ray Phase-Contrast Micro-CT. Radiology, 2021, 298, 135-146.	3.6	21
215	Alterations of gut microbiota composition in post-finasteride patients: a pilot study. Journal of Endocrinological Investigation, 2021, 44, 1263-1273.	1.8	21
216	Prospectively assessing serum neurofilament light chain levels as a biomarker of <scp>paclitaxelâ€induced</scp> peripheral neurotoxicity in breast cancer patients. Journal of the Peripheral Nervous System, 2022, 27, 166-174.	1.4	21

#	Article	IF	Citations
217	The Role of Growth Factors in the Prevention and Treatment of Chemotherapy-Induced Peripheral Neurotoxicity. Current Drug Safety, 2006, 1, 35-42.	0.3	20
218	Different effects of erythropoietin in cisplatinâ€•and docetaxelâ€•induced neurotoxicity: An in vitro study. Journal of Neuroscience Research, 2010, 88, 3171-3179.	1.3	20
219	Patients' and physicians' interpretation of chemotherapyâ€•induced peripheral neurotoxicity. Journal of the Peripheral Nervous System, 2019, 24, 111-119.	1.4	20
220	Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy. Journal of Neuroimmunology, 2020, 345, 577288.	1.1	20
221	Antibody against tumor necrosis factor-Î± reduces bortezomib-induced allodynia in a rat model. Anticancer Research, 2013, 33, 5453-9.	0.5	20
222	Modulation of the central memory and Tr1-like regulatory T cells in multiple sclerosis patients responsive to interferon-beta therapy. Multiple Sclerosis Journal, 2012, 18, 788-798.	1.4	19
223	Clinical and neurophysiological serial assessments of brentuximab vedotin-associated peripheral neuropathy. Leukemia and Lymphoma, 2019, 60, 2806-2809.	0.6	19
224	Clinician-rated measures for distal symmetrical axonal polyneuropathy. Neurology, 2019, 93, 346-360.	1.5	19
225	Evaluation by somatosensory evoked potentials of the neurotoxicity of cisplatin alone or in combination with glutathione. Italian Journal of Neurological Sciences, 1992, 13, 643-647.	0.1	18
226	Continuous Buprenorphine Delivery Effect in Streptozotocine-Induced Painful Diabetic Neuropathy in Rats. Journal of Pain, 2009, 10, 961-968.	0.7	18
227	Neurophysiological examination of dorsal sural nerve. Muscle and Nerve, 2012, 46, 891-894.	1.0	18
228	Lenalidomide in patients with chemotherapyâ€•induced polyneuropathy and relapsed or refractory multiple myeloma: results from a singleâ€•centre prospective study. Journal of the Peripheral Nervous System, 2013, 18, 19-24.	1.4	18
229	Calmangafodipir Reduces Sensory Alterations and Prevents Intraepidermal Nerve Fibers Loss in a Mouse Model of Oxaliplatin Induced Peripheral Neurotoxicity. Antioxidants, 2020, 9, 594.	2.2	18
230	Functionalized Mesoporous Silica Nanoparticles: A Possible Strategy to Target Cancer Cells Reducing Peripheral Nervous System Uptake. Current Medicinal Chemistry, 2013, 20, 2589-2600.	1.2	18
231	Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: Systematic review and evidence-based recommendations. Critical Reviews in Oncology/Hematology, 2022, 171, 103575.	2.0	18
232	Antiepileptic Drugs and Peripheral Nerve Function: A Multicenter Screening Investigation of 141 Patients with Chronic Treatment. Epilepsia, 1993, 34, 323-331.	2.6	17
233	Toxic neuropathies: Chemotherapy Induced Peripheral Neurotoxicity. Current Opinion in Neurology, 2019, 32, 676-683.	1.8	17
234	Characterization of and protection from neurotoxicity induced by oxaliplatin, bortezomib and epothilone-B. Anticancer Research, 2014, 34, 517-23.	0.5	17

#	Article	IF	Citations
235	Multimodal Analysis in Acute and Chronic Experimental Autoimmune Encephalomyelitis. Journal of NeuroImmune Pharmacology, 2013, 8, 238-250.	2.1	16
236	Antitumoral Effect of Hibiscus sabdariffa on Human Squamous Cell Carcinoma and Multiple Myeloma Cells. Nutrition and Cancer, 2016, 68, 1161-1170.	0.9	16
237	Are sigma receptor modulators a weapon against multiple sclerosis disease?. Future Medicinal Chemistry, 2017, 9, 2029-2051.	1.1	16
238	Oxaliplatin induces pH acidification in dorsal root ganglia neurons. Scientific Reports, 2018, 8, 15084.	1.6	16
239	An integrative approach to cisplatin chronic toxicities in mice reveals importance of organic cation-transporter-dependent protein networks for renoprotection. Archives of Toxicology, 2019, 93, 2835-2848.	1.9	16
240	Emerging pharmacological strategies for the management of chemotherapy-induced peripheral neurotoxicity (CIPN), based on novel CIPN mechanisms. Expert Review of Neurotherapeutics, 2020, 20, 1005-1016.	1.4	16
241	Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity. Neurology, 2021, 97, e660-e672.	1.5	16
242	Effects of repeated administration of low doses of cisplatin on the rat nervous system. International Journal of Tissue Reactions, 1991, 13, 151-7.	0.2	16
243	Neuroprotectant drugs in cisplatin neurotoxicity. Anticancer Research, 1996, 16, 3149-59.	0.5	16
244	Ghrelin agonist HM01 attenuates chemotherapy-induced neurotoxicity in rodent models. European Journal of Pharmacology, 2018, 840, 89-103.	1.7	15
245	Relevance of diagnostic investigations in chronic inflammatory demyelinating poliradiculoneuropathy: Data from the Italian CIDP database. Journal of the Peripheral Nervous System, 2020, 25, 152-161.	1.4	15
246	Chronic inflammatory demyelinating polyradiculoneuropathy: can a diagnosis be made in patients not fulfilling electrodiagnostic criteria?. European Journal of Neurology, 2021, 28, 620-629.	1.7	15
247	Distribution Of Paclitaxel Within The Nervous System Of The Rat After Repeated Intravenous Administration. Journal of the Peripheral Nervous System, 2001, 6, 61-61.	1.4	14
248	Opposite effects of interferon-beta on new B and T cell release from production sites in multiple sclerosis patients. Journal of Neuroimmunology, 2011, 240-241, 147-150.	1.1	14
249	Drugs for the treatment of peripheral neuropathies. Expert Opinion on Pharmacotherapy, 2016, 17, 381-394.	0.9	14
250	Identification of dual Sigma1 receptor modulators/acetylcholinesterase inhibitors with antioxidant and neurotrophic properties, as neuroprotective agents. European Journal of Medicinal Chemistry, 2018, 158, 353-370.	2.6	14
251	Anti-tumor Efficacy Assessment of the Sigma Receptor Pan Modulator RC-106. A Promising Therapeutic Tool for Pancreatic Cancer. Frontiers in Pharmacology, 2019, 10, 490.	1.6	14
252	SARS-CoV-2 infection among asymptomatic homebound subjects in Milan, Italy. European Journal of Internal Medicine, 2020, 78, 161-163.	1.0	14

#	Article	IF	Citations
253	Genetic factors influencing the development of vincristine-induced neurotoxicity. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 215-226.	1.5	14
254	Calcium-related Neurotoxicity of Oxaliplatin: Understanding the Mechanisms to Drive Therapy. Current Medicinal Chemistry, 2015, 22, 3682-3694.	1.2	14
255	Calcium and Magnesium Prophylaxis for Oxaliplatin-Related Neurotoxicity: Is It a Trade-off Between Drug Efficacy and Toxicity?. Oncologist, 2011, 16, 1667-1668.	1.9	13
256	Drug Transporters in Chemotherapy Induced Peripheral Neurotoxicity:Current Knowledge and Clinical Implications. Current Medicinal Chemistry, 2011, 18, 329-341.	1.2	13
257	Off-treatment course of cisplatin-induced dorsal root ganglia neuronopathy in rats. In Vivo, 1994, 8, 313-6.	0.6	13
258	Current Status and Future Prospective of Immunointervention in Multiple Sclerosis. Current Medicinal Chemistry, 2006, 13, 2329-2343.	1.2	12
259	A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer. Investigational New Drugs, 2014, 32, 1123-1133.	1.2	12
260	Approaches to measure paediatric chemotherapy-induced peripheral neurotoxicity: a systematic review. Lancet Haematology,the, 2020, 7, e408-e417.	2.2	12
261	Breast radiotherapy with kilovoltage photons and gold nanoparticles as radiosensitizer: An in vitro study. Medical Physics, 2022, 49, 568-578.	1.6	12
262	Effects of Exposure to Low Oxygen Pressure on the Central Nervous System. Sports Medicine, 1992, 13, 1-7.	3.1	11
263	Actively induced EAE in Lewis rats: Characterization of spleen and spinal cord infiltrating lymphocytes by flow cytometry during the course of the disease. Journal of Neuroimmunology, 2008, 199, 67-74.	1.1	11
264	Liability of the voltageâ€gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatinâ€induced peripheral neurotoxicity. Journal of the Peripheral Nervous System, 2019, 24, 298-303.	1.4	11
265	Human Intravenous Immunoglobulin Alleviates Neuropathic Symptoms in a Rat Model of Paclitaxel-Induced Peripheral Neurotoxicity. International Journal of Molecular Sciences, 2021, 22, 1058.	1.8	11
266	Topology of two DBI receptors in human lymphocytes. Life Sciences, 1993, 52, 1265-1277.	2.0	11
267	Optimal outcome measures for assessing exercise and rehabilitation approaches in chemotherapy-induced peripheral-neurotoxicity: Systematic review and consensus expert opinion. Expert Review of Neurotherapeutics, 2022, 22, 65-76.	1.4	11
268	Ultrastructural aspects of DRG satellite cell involvement in experimental cisplatin neuronopathy. Journal of Submicroscopic Cytology and Pathology, 1995, 27, 417-25.	0.3	11
269	Chemotherapy-induced peripheral neurotoxicity: how can we improve knowledge?. Lancet Oncology, The, 2009, 10, 539-540.	5.1	10
270	The ventral caudal nerve: a physiologicâ€morphometric study in three different rat strains. Journal of the Peripheral Nervous System, 2010, 15, 140-146.	1.4	10

#	Article	IF	Citations
271	Evaluation of the Profile and Mechanism of Neurotoxicity of Water-Soluble [Cu(P)4]PF6 and [Au(P)4]PF6 (P = thp or PTA) Anticancer Complexes. Neurotoxicity Research, 2018, 34, 93-108.	1.3	10
272	Altered methylation pattern of the SRD5A2 gene in the cerebrospinal fluid of post-finasteride patients: a pilot study. Endocrine Connections, 2019, 8, 1118-1125.	0.8	10
273	Global Transcriptomic Profile of Dorsal Root Ganglion and Physiological Correlates of Cisplatin-Induced Peripheral Neuropathy. Nursing Research, 2019, 68, 145-155.	0.8	10
274	The relevance of multimodal assessment in experimental oxaliplatin-induced peripheral neurotoxicity. Experimental Neurology, 2020, 334, 113458.	2.0	10
275	Exploring the RC-106 Chemical Space: Design and Synthesis of Novel (E)-1-(3-Arylbut-2-en-1-yl)-4-(Substituted) Piperazine Derivatives as Potential Anticancer Agents. Frontiers in Chemistry, 2020, 8, 495.	1.8	10
276	Blood molecular biomarkers for chemotherapy-induced peripheral neuropathy: From preclinical models to clinical practice. Neuroscience Letters, 2021, 749, 135739.	1.0	10
277	Chronic axonal sensory and autonomic polyneuropathy without motor involvement: a new ?chronic inflammatory neuropathy??. European Journal of Neurology, 1999, 6, 249-253.	1.7	9
278	A post-marketing study on immunomodulating treatments for relapsing-remitting multiple sclerosis in Lombardia: preliminary results. Neurological Sciences, 2005, 26, s171-s173.	0.9	9
279	Targeting Cancer and Neuropathy with Histone Deacetylase Inhibitors:Two Birds with One Stone?. Current Cancer Drug Targets, 2008, 8, 266-274.	0.8	9
280	Tissue Distribution of Glutamate Carboxypeptidase II (GCPII) with a Focus on the Central and Peripheral Nervous System. Current Medicinal Chemistry, 2012, 19, 1277-1281.	1.2	9
281	Serum neurofilament light chain levels as biomarker of paclitaxel-induced cognitive impairment in patients with breast cancer: a prospective study. Supportive Care in Cancer, 2022, 30, 1807-1814.	1.0	9
282	Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian database. Neurological Sciences, 2022, 43, 3939-3947.	0.9	9
283	Ultrastructural organization of lamina VI of the spinal cord of the cat. Progress in Neurobiology, 1985, 24, 293-331.	2.8	8
284	Lipid-free versus lipid-bound P2 protein-induced experimental allergic neuritis: Clinicopathological, neurophysiological, and immunological study. Journal of Neuroscience Research, 2000, 62, 709-716.	1.3	8
285	Expression, distribution and glutamate uptake activity of high affinity-excitatory aminoacid transporters in in vitro cultures of embryonic rat dorsal root ganglia. Neuroscience, 2011, 192, 275-284.	1.1	8
286	Islet Transplantation and Insulin Administration Relieve Long-Term Complications and Rescue the Residual Endogenous Pancreatic Î² Cells. American Journal of Pathology, 2013, 183, 1527-1538.	1.9	8
287	An unusual transthyretin gene missense mutation (TTR Phe33Val) linked to familial amyloidotic polyneuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2004, 11, 121-124.	1.4	7
288	Effects of pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis. Journal of Neuroimmunology, 2005, 168, 111-117.	1.1	7

#	Article	IF	Citations
289	Low-dose cisplatin protects human neuroblastoma SH-SY5Y cells from paclitaxel-induced apoptosis. Molecular Cancer Therapeutics, 2005, 4, 1439-1447.	1.9	7
290	Severe, reversible nelarabineâ€induced neuropathy and myelopathy. Journal of the Peripheral Nervous System, 2016, 21, 154-156.	1.4	7
291	Tubulin binding potentially clears up Bortezomib and Carfilzomib differential neurotoxic effect. Scientific Reports, 2021, 11, 10523.	1.6	7
292	Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values. Clinical Neurophysiology, 2022, 138, 231-240.	0.7	7
293	Synchrotron-based photon activation therapy effect on cisplatin pre-treated human glioma stem cells. Anticancer Research, 2014, 34, 5351-5.	0.5	7
294	Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer, 1995, 76, 916-917.	2.0	6
295	Extracorporeal photochemotherapy reduces the incidence of relapses in experimental allergic encephalomyelitis in DA rats. Journal of Neurology, 2001, 248, 535-536.	1.8	6
296	Expression of CD38 in Human Neuroblastoma Sh-SY5Y Cells. International Journal of Immunopathology and Pharmacology, 2008, 21, 97-105.	1.0	6
297	Bortezomib-induced peripheral neuropathy: facts and genes. Lancet Oncology, The, 2011, 12, 120-121.	5.1	6
298	Comparing the different response of PNS and CNS injured neurons to mesenchymal stem cell treatment. Molecular and Cellular Neurosciences, 2018, 86, 16-24.	1.0	6
299	Establishing sample-preparation protocols for X-ray phase-contrast CT of rodent spinal cords: Aldehyde fixations and osmium impregnation. Journal of Neuroscience Methods, 2020, 339, 108744.	1.3	6
300	Intravenous immunoglobulin treatment for mild Guillain-BarrÃ© syndrome: an international observational study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1080-1088.	0.9	6
301	Reversal of Bortezomib-Induced Neurotoxicity by Suvecaltamide, a Selective T-Type Ca-Channel Modulator, in Preclinical Models. Cancers, 2021, 13, 5013.	1.7	6
302	Systems Pharmacology Modeling Identifies a Novel Treatment Strategy for Bortezomib-Induced Neuropathic Pain. Frontiers in Pharmacology, 2021, 12, 817236.	1.6	6
303	Extracorporeal photochemotherapy reduces the severity of Lewis rat experimental allergic encephalomyelitis through a modulation of the function of peripheral blood mononuclear cells. Journal of Biological Regulators and Homeostatic Agents, 2004, 18, 9-17.	0.7	6
304	Bortezomib-induced peripheral neurotoxicity in human multiple myeloma-bearing mice. Journal of Biological Regulators and Homeostatic Agents, 2015, 29, 115-24.	0.7	6
305	Toxic and Drug-Induced Neuropathies. , 2007, , 871-883.		5
306	Exploiting CD38-mediated endocytosis for immunoliposome internalization. Anti-Cancer Drugs, 2008, 19, 599-605.	0.7	5

#	Article	IF	Citations
307	Cryoglobulinaemic neuropathy: lack of progression in patients with good haematological control. Acta Neurologica Scandinavica, 1995, 92, 372-375.	1.0	5
308	Editorial [Hot Topic: Regulation of Glutamate Synthesis Via Inhibition of Glutamate Carboxypeptidase II (GCPII): An Effective Method to Treat Central and Peripheral Nervous System Disorders (Guest Editors:) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.2	5
309	Sex dimorphism in an animal model of multiple sclerosis: Focus on pregnenolone synthesis. Journal of Steroid Biochemistry and Molecular Biology, 2020, 199, 105596.	1.2	5
310	Clinical and biochemical markers in CIPN: A reappraisal. Revue Neurologique, 2021, 177, 890-907.	0.6	5
311	Protective Effect of Human Mesenchymal Stem Cells on the Survival of Pancreatic Islets. International Journal of Stem Cells, 2020, 13, 116-126.	0.8	5
312	Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome. Current Pharmaceutical Design, 2014, 20, 1831-1839.	0.9	5
313	Immunomodulating effects of extracorporeal photochemotherapy in rat experimental allergic encephalomyelitis. International Journal of Tissue Reactions, 2001, 23, 21-31.	0.2	5
314	Neuropathological changes in the peripheral nervous system and spinal cord in a transgenic mouse model of Niemann-Pick disease type A. , 2009, 28, 263-74.		5
315	The still under-investigated role of cognitive deficits in PML diagnosis. Multiple Sclerosis and Demyelinating Disorders, 2017, 2, .	1.1	4
316	Voltageâ€gated sodium channel dysfunction and the search for other satellite channels in relation to acute oxaliplatinâ€induced peripheral neurotoxicity. Journal of the Peripheral Nervous System, 2019, 24, 360-361.	1.4	4
317	Impact of environmental factors and physical activity on disability and quality of life in CIDP. Journal of Neurology, 2020, 267, 2683-2691.	1.8	4
318	Metabolomics markers in Neurology: current knowledge and future perspectives for therapeutic targeting. Expert Review of Neurotherapeutics, 2020, 20, 725-738.	1.4	4
319	In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells. International Journal of Molecular Sciences, 2021, 22, 8230.	1.8	4
320	Cannabinoids: an Effective Treatment for Chemotherapy-Induced Peripheral Neurotoxicity?. Neurotherapeutics, 2021, 18, 2324-2336.	2.1	4
321	Ubiquitin Proteasome System and Microtubules Are Master Regulators of Central and Peripheral Nervous System Axon Degeneration. Cells, 2022, 11, 1358.	1.8	4
322	Sportâ€"related peripheral nerve injuries: part 1. Sport Sciences for Health, 2005, 1, 55-60.	0.4	3
323	A new device to study ex-vivo the effects of extracorporeal photochemotherapy on the immune system. Journal of Photochemistry and Photobiology B: Biology, 2007, 88, 68-75.	1.7	3
324	Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue. Pain Management, 2013, 3, 417-419.	0.7	3

#	Article	IF	Citations
325	Toxicities of Therapeutic Agents Used in Medicine. Toxics, 2016, 4, 14.	1.6	3
326	How can neuroplasticity be utilized to improve neuropathy symptoms?. Expert Review of Neurotherapeutics, 2016, 16, 1235-1236.	1.4	3
327	The Toxic Neuropathy Consortium of the Peripheral Nerve Society. Journal of the Peripheral Nervous System, 2019, 24, S4-S5.	1.4	3
328	The neurophysiological lesson from the Italian CIDP database. Neurological Sciences, 2021, , 1.	0.9	3
329	Clinical and preclinical features of eribulin-related peripheral neuropathy. Experimental Neurology, 2022, 348, 113925.	2.0	3
330	The effect of Photon Activation Therapy on cisplatin pre-treated human tumour cell lines: comparison with conventional X-ray irradiation. Journal of Biological Regulators and Homeostatic Agents, 2013, 27, 477-85.	0.7	3
331	Rigosertib and Cholangiocarcinoma: A Cell Cycle Affair. International Journal of Molecular Sciences, 2022, 23, 213.	1.8	3
332	Making Connections: Mesenchymal Stem Cells Manifold Ways to Interact with Neurons. International Journal of Molecular Sciences, 2022, 23, 5791.	1.8	3
333	MRI evaluation of a case of herpes zoster ophthalmicus with delayed contralateral hemiplegia. Italian Journal of Neurological Sciences, 1990, 11, 297-300.	0.1	2
334	Evaluation of Cisplatin Neuroprotection by NT-3. Annals of Neurology, 1996, 39, 827-827.	2.8	2
335	Guidelines by the European Federation of Neurological Societies (EFNS) subcommittee for Continuing Medical Education (CME) - modification 2003. EFNS - approval of CME. European Journal of Neurology, 2004, 11, 145-151.	1.7	2
336	Sportâ€“related peripheral nerve injuries: part 2. Sport Sciences for Health, 2005, 1, 61-67.	0.4	2
337	Exposureâ€“Response Relationship of the Synthetic Epothilone Sagopilone in a Peripheral Neurotoxicity Rat Model. Neurotoxicity Research, 2012, 22, 91-101.	1.3	2
338	Distal pain and carpal tunnel syndrome diagnosis among cashiers: a longitudinal study. International Archives of Occupational and Environmental Health, 2017, 90, 741-746.	1.1	2
339	Early Stimulation of TREK Channel Transcription and Activity Induced by Oxaliplatin-Dependent Cytosolic Acidification. International Journal of Molecular Sciences, 2020, 21, 7164.	1.8	2
340	Abstract 934: Electrophysiological, behavioural and molecular characterization of the neuropathic pain in bortezomib-induced peripheral neuropathy. , 2012, , .		2
341	Considerations for a Reliable In Vitro Model of Chemotherapy-Induced Peripheral Neuropathy. Toxics, 2021, 9, 300.	1.6	2
342	Endoneural vessel involvement in hypothyroidism. Italian Journal of Neurological Sciences, 1987, 8, 259-264.	0.1	1

#	Article	IF	Citations
343	Histological Features of Nerve Fibers and Endoneural Vessels in a Case of Wegenerâ€™s Granulomatosis. European Neurology, 1988, 28, 77-80.	0.6	1
344	CLINICAL AND NEUROPHYSIOLOGIC EVALUATION OF THE EFFECT OF CISPLATIN ADMINISTRATION ON THE MOTOR NERVES. International Journal of Oncology, 1993, 2, 81-4.	1.4	1
345	Homozygous hypertrophic hereditary motor and sensory neuropathies. Italian Journal of Neurological Sciences, 1994, 15, 5-14.	0.1	1
346	Risk factors for the development of severe cisplatin neurotoxicity. International Journal of Oncology, 1997, 11, 365-70.	1.4	1
347	LIPIDâ€FREE VS. LIPIDâ€BOUND EXPERIMENTAL ALLERGIC NEURITIS IN THE LEWIS RAT. Journal of the Peripheral Nervous System, 2000, 5, 36-37.	1.4	1
348	RAT in vivo models of taxanes' peripheral neurotoxicity following chronic intravenous administration. Journal of the Peripheral Nervous System, 2004, 9, 104-104.	1.4	1
349	Chemotherapyâ€induced peripheral neurotoxicity: Facts, needs and future directions. Journal of the Peripheral Nervous System, 2019, 24, S86-S87.	1.4	1
350	Reply to a Comment Paper on the Published Paper by Canta, A. et al: â€œCalmangafodipir Reduces Sensory Alterations and Prevents Intraepidermal Nerve Fibers Loss in a Mouse Model of Oxaliplatin Induced Peripheral Neurotoxicityâ€â€”Antioxidants 2020, 9, 594. Antioxidants, 2020, 9, 807.	2.2	1
351	Electrophysiological Assessments in Peripheral Nerves and Spinal Cord in Rodent Models of Chemotherapy-Induced Painful Peripheral Neuropathy. Neuromethods, 2021, , 133-161.	0.2	1
352	Prolonged distal motor latency of median nerve does not improve diagnostic accuracy for CIDP. Journal of Neurology, 2021, , 1.	1.8	1
353	Abstract 4384: Characterization of the painful peripheral neuropathy induced by oxaliplatin-based chemotherapy in mice. , 2011, , .		1
354	Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD). Blood, 2011, 118, 1821-1821.	0.6	1
355	ETNK1 Mutations in Atypical Chronic Myeloid Leukemia Induce a Mutator Phenotype That Can be Reverted with Phosphoethanolamine. Blood, 2020, 136, LBA-5-LBA-5.	0.6	1
356	Cisplatin neuropathy. Neurology, 1995, 45, 596; author reply 596-7.	1.5	1
357	Sporadic adult onset distal myopathy.. Journal of Neurology, Neurosurgery and Psychiatry, 1988, 51, 468-469.	0.9	0
358	Paraneoplastic antibodies. Neurology, 1995, 45, 2120-2121.	1.5	0
359	Neuroprotection by erythropoietin against taxane induced peripheral neuropathy. Cytokine, 2009, 48, 53.	1.4	0
360	186 CR4056: A NOVEL POTENT ANTIâ€NOCICEPTIVE AGENT FOR SEVERAL ANIMAL MODELS OF NEUROPATHIC PAIN. European Journal of Pain Supplements, 2010, 4, 55-55.	0.0	0

#	Article	IF	Citations
361	Evaluation and monitoring of peripheral nerve function. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 104, 163-171.	1.0	0
362	Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective. Annals of Oncology, 2013, 24, 1418-1419.	0.6	0
363	The lipogenic regulator Sterol Regulatory Element Binding Factor-1c is required to maintain peripheral nerve structure and function. SpringerPlus, 2015, 4, L45.	1.2	0
364	Nerve pathology in animal models of neuropathies. Journal of the Peripheral Nervous System, 2021, 26 Suppl 2, S61-S68.	1.4	0
365	Assessment of Protein as a in Rodent Models of Toxic-Induced Peripheral. Neuromethods, 2021, , 267-275.	0.2	0
366	Immunoglobulin free light chains as a diagnostic and prognostic biomarker in multiple sclerosis: A real life study. Journal of the Neurological Sciences, 2021, 429, 117773.	0.3	0
367	Pixantrone maleate. Drugs of the Future, 2007, 32, 0703.	0.0	0
368	Glutamate carboxypeptidase II inhibition IN rat models of chemotherapy-induced peripheral neurotoxicity (CIPN). Journal of Clinical Oncology, 2008, 26, 9558-9558.	0.8	0
369	Peripheral Neurotoxicity of Platinum Compounds. , 2009, , 359-364.		0
370	Abstract 657: The new analgesic CR4056 effectively abrogates neuropathic pain induced by Bortezomib in rats. , 2011, , .		0
371	Abstract 933: Peripheral neuropathy induced by chronic administration of Cisplatin, taxol and bortezomib in several murine models. , 2012, , .		0
372	Abstract 5679: Characterizationin vivoof two different molecular mechanisms involved in the development of bortezomib-induced peripheral neuropathy. , 2012, , .		0
373	Sigma 1 receptor modulators as a new weapon against multiple sclerosis. BioDiscovery, 0, 20, e14565.	0.1	0
374	Effects induced in lungs by UFPs from different anthropogenic sources. , 2017, , .		0
375	Differential Contribution of Neuronal Uptake Transporters to Oxaliplatin Peripheral Neurotoxicity. FASEB Journal, 2020, 34, 1-1.	0.2	0
376	Blood-nerve barrier of endoneural vessels in experimentally-induced hypothyroidism in rats. International Journal of Tissue Reactions, 1989, 11, 137-42.	0.2	0